EMA approves Novartis' diabetes drugs Galvus and Eucreas
Singapore: European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued two positive opinions for new indications for the use of Novartis' Galvus (vildagliptin) and Eucreas (vildagliptin and metformin) in combination with other treatments for type 2 diabetes patients.
The first positive opinion was for vildagliptin in combination with insulin, and with or without metformin, for patients with type 2 diabetes when diet, exercise and a stable dose of insulin do not result in glycemic control.
The second positive opinion was for vildagliptin in triple combination with metformin and a sulphonylurea for the treatment of type 2 diabetes when diet and exercise plus dual therapy with these two agents do not provide adequate glycemic control.
"These CHMP positive opinions are important milestones in our efforts to offer physicians and patients effective and generally well-tolerated additional treatment options to help reach and maintain blood sugar goals," says Dr David Morris, primary care franchise, and head, development, Novartis Pharmaceuticals.
